SABS

SAB Biotherapeutics, Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Sioux Falls, South Dakota. The company went public in February 2021 through an initial public offering. SAB Biotherapeutics specializes in developing innovative immunotherapies using a unique platform that produces fully human antibodies from genetically engineered cattle, representing a novel approach in the biotechnology industry for creating therapeutic treatments without requiring human donors.